The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Open accessAbstract
Summary Background Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine (DAC) and deoxyguanosine that is resistant to degradation by cytidine deaminase. Methods This is a first-in-human pharmacokinetic (PK)- and pharmacodynamic (PD)-guided Phase 1 dose-escalation study in adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients with MDS or AML refractory to, or relapsed after, standard treatment were randomly assigned to one of two regimens of subcutaneous (SC) guadecitabine: Daily×5 or Once Weekly for three weeks. Stratification was based on disease (MDS vs. AML). Treatment assignment was not blinded. A Twice Weekly for three weeks regimen was later added to the study. All regimens were given in 28-day cycles. The primary objective was the safety profile of all regimens and the recommended dose and schedule for phase 2 by either maximum tolerated dose (MTD) or biologically effective dose (BED). All patients who received at least one treatment were included in the analyses. Enrollment is complete and all patients have finished treatment. This study is registered with ClinicalTrials.gov, number NCT01261312. Findings 93 patients were treated (74 AML and 19 MDS): 44 on Daily×5 (3–125 mg/m2/d), 34 on Once Weekly (6–125 mg/m2/d), and 15 on Twice Weekly (60 and 90 mg/m2/d). Guadecitabine SC produced a longer exposure window and half-life, and lower Cmax, of plasma DAC than intravenous DAC. The MTD was 90 mg/m2 in MDS on the Daily×5 regimen but was not reached in AML or on the other regimens. The most common Grade ≥3 adverse events were febrile neutropenia (38/93, 41%), pneumonia (27/93, 29%), thrombocytopenia and anemia (23/93, 25% each), and sepsis (16/93, 17%). The most common serious adverse events (SAEs) were febrile neutropenia (29/93, 31%), pneumonia (26/93, 28%), and sepsis (16/93, 17%). Potent dose-related DNA demethylation occurred on the daily regimen, reaching a plateau at 60 mg/m2 Daily×5 (designated as BED). Responses were seen in heavily pretreated patients including six responders (two complete response [CR], two CR with incomplete blood count recovery [CRi], one CR with incomplete platelet recovery [CRp], and one partial response [PR]) in AML patients and two marrow complete response (mCR) in MDS patients. Responders showed significantly more demethylation than non-responders. Interpretation Guadecitabine SC at 60 mg/m2 Daily×5 is well-tolerated, easily administered, and biologically and clinically active in both MDS and AML; it warrants testing in phase 2 studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements
Yang, A. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh032 · Cited by 1,033
Issa, J.-P. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 446
Self-citationGenome-Wide Profiling of DNA Methylation Reveals a Class of Normally Methylated CpG Island Promoters
Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., Shu, J., Chen, X., Waterland, R. A., & Issa, J.-P. J. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030181 · Cited by 389
Self-citationPhase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4169 · Cited by 315
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Jabbour, E., Garcia‐Manero, G., Batty, N., Shan, J., O'Brien, S., Cortes, J., Ravandi, F., Issa, J., & Kantarjian, H. (2010) · Cancer · doi:10.1002/cncr.25247 · Cited by 276
Self-citationDelivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides
Yoo, C. B., Jeong, S., Egger, G., Liang, G., Phiasivongsa, P., Tang, C., Redkar, S., & Jones, P. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0251 · Cited by 219
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Self-citationEpigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Metadata
- Authors
- Issa, J.-P. J., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O'Connell, C., Yee, K., Tibes, R., Griffiths, E. A., Walsh, K., Daver, N., Chung, W., Naim, S., Taverna, P., Oganesian, A., Hao, Y., Lowder, J. N., Azab, M., & Kantarjian, H.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 16
- Issue
- 9
- Pages
- 1099-1110
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2115528152
- Cited by
- 283
- References
- 17
- FWCI
- 28.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00038-8
- The paper
- Issa, J.-P. J., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O'Connell, C., Yee, K., Tibes, R., Griffiths, E. A., Walsh, K., Daver, N., Chung, W., Naim, S., Taverna, P., Oganesian, A., Hao, Y., Lowder, J. N., Azab, M., & Kantarjian, H. (2015). Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00038-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.